Article Sidebar
Published:
Feb 13, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
MiR-493-5p alleviates lipopolysaccharide-induced inflammation in ATDC5 chondrogenic cells by targeting TAB2
Abstract
Purpose: To investigate the effect of miR-493-5p in lipopolysaccharide (LPS) -induced ATDC5 chondrogenic cells.
Methods: The MTT assay was used to determine the viability of LPS-induced ATDC5 cells. ENCORI (starbase.sysu.edu.cn/) was used to predict the target of miR-493-5p. Quantitative reverse-transcription-polymerase chain reaction (qRT-PCR) was used to determine miR-493-5p expression in ATDC5 controlled cells and cells treated with various combinations of LPS, negative control miRNA (NC), miR-493-5p mimic, TAB2 overexpression vector, and miR-493-5p inhibitor. qRT-PCR, while western blot was used to assess TAB2 mRNA and protein expression levels in control, LPS, LPS + NC, LPS + miR-493-5p mimic, and LPS + miR-493-5p inhibitor groups. The qRT-PCR and ELISA were used to evaluate TNF-α, IL-18, and IL-1β expressions in control, NC, LPS, LPS + NC, miR-493-5p mimic, and LPS + miR-493-5p mimic. Furthermore, the two techniques were also used determine LPS + miR-493-5p inhibitor, LPS + TAB2 overexpression, and LPS + TAB2 overexpression + miR-493-5p mimic groups.
Results: MiR-493-5p expression was downregulated in LPS-induced ATDC5 cells (p < 0.001). Overexpression of miR-493-5p increased LPS-induced ATDC5 cell viability but decreased expression of inflammatory factors (p < 0.001). MiR-493-5p targeted and inhibited TAB2 expression in LPS-induced ATDC5 cells (p < 0.001). TAB2 overexpression reversed the suppression of TAB2 by miR-493-5p in LPS-induced ATDC5 cell injury (p < 0.001).
Conclusion: MiR-493-5p alleviates LPS-induced inflammation of ATDC5 chondrogenic cells by targeting TAB2. Thus, miR-493-5p and TAB2 have potentials for use as clinical therapeutic targets for OA.
